Team:Bielefeld-CeBiTec/Project/Library/Scaffolds
Library Project
Scaffolds
What is a Library?
Our project is based on the construction of an adequate library, which is defined as a collection of identical plasmids that only vary in the protein coding sequences (CDS). These CDS are designed to possess optimized and region specific randomized subregions displaying high variability. Upon transformation of the randomized plasmids into E. coli a heterogeneous culture is obtained with each colony carrying a different insert translating into different binding proteins (Osoegawa K et al 2001).
One major advantage of our library is the availability of a wide range of different binding proteins as starting point for the directed evolution process. Completely new antibodies or variations of existing ones could serve as starting material.
By creating such a large variety, we are aiming for the highest chance for a possible binder. By adjusting the variable regions and their nucleic acid scheme we can specify the target further but still have leverage to cover a wide range of possible targets in the beginning (see Library - Design and Construction).
In order to identify suitable binding proteins for an appropriate scaffold of our library, we compared different types of antibodies and antibody mimetics from various sources. Antibody mimetics also show better accessibility to genetic engineering like construction of fusion proteins or incorporation of modifiable amino acids thus allowing the combination with fluorophores or drugs for targeted drug delivery (Skerra et al 2007). After deep and thorough investigation we decided to use Monobodies and Nanobodies. Although commonly used antibodies might be more robust, they are outperformed ten times by Mono- and Nanobodies in their smaller size (15 kDa vs. 150 kDa) and stability. This enables to penetrate depth, even in hard tissue (Ahmad ZA et al, 2012). Additionally, Nano- and Monobody binding proteins are rapidly cleared from the blood and have lower retention time in non-target tissues (Ahmad ZA et al, 2012).
One major advantage of our library is the availability of a wide range of different binding proteins as starting point for the directed evolution process. Completely new antibodies or variations of existing ones could serve as starting material.
By creating such a large variety, we are aiming for the highest chance for a possible binder. By adjusting the variable regions and their nucleic acid scheme we can specify the target further but still have leverage to cover a wide range of possible targets in the beginning (see Library - Design and Construction).
In order to identify suitable binding proteins for an appropriate scaffold of our library, we compared different types of antibodies and antibody mimetics from various sources. Antibody mimetics also show better accessibility to genetic engineering like construction of fusion proteins or incorporation of modifiable amino acids thus allowing the combination with fluorophores or drugs for targeted drug delivery (Skerra et al 2007). After deep and thorough investigation we decided to use Monobodies and Nanobodies. Although commonly used antibodies might be more robust, they are outperformed ten times by Mono- and Nanobodies in their smaller size (15 kDa vs. 150 kDa) and stability. This enables to penetrate depth, even in hard tissue (Ahmad ZA et al, 2012). Additionally, Nano- and Monobody binding proteins are rapidly cleared from the blood and have lower retention time in non-target tissues (Ahmad ZA et al, 2012).
Monobodies
Monobodies, also called adnectines, are synthetic antibody mimetics that originate from the tenth human fibronectin type 3 domain. Fibronectin is a rather large protein that is essential in the formation of the extracellular matrix and cell-cell interactions (Koide A, Koide S, 2007). In 1998 the research group of Akiko Koide discovered that the fibronectin scaffold possesses similar binding properties like antibodies (Koide A et al, December 1998). Since then continuous research lead to appliance in treatment of diseases like glioblastoma multiform (Bloom L, Calabro V, July 2009) or chronic myelogenous leukaemia (Grebien F et al, 2011) The structure of Monobodies is similar to immunoglobulin domains (Lipovsek, D, 2010). The original three dimensional structure of the scaffold is a β-sandwich but with seven β-strands instead of nine which are common in the variable domain of the heavy chain domain of regular antibodies and three surface loops on each end (Koide, A; Koide, S, 2007)(Koide S, Koide A, Lipovšek D, 2012). They have a high stability and due to their small size, 10 kDa, and they penetrate deep into tissue (Koide, A; Koide, S, 2007). Another outstanding feature that they can be functionally expressed in the E. coli cytoplasm and thereby can be produced simple and at low cost in culture. This is due to the absence of disulphide bonds which are unlikely to form in the E. coli cytoplasm. This makes them compatible with virtually any display technologies (Koide A, Koide S, 2007) and is therefore a suitable canditate for our in vivo system. By randomising the amino acid sequence of the CDR-like loops an initial library is created. The extensive loop sequence variation is tolerated by the structure so it stays stable (Batori, V. et al. 2002). Thus allowing binding of the target with high affinity and selectivity (Skerra, A, 2007)(Gebauer, M. and Skerra, A,2009)( Gill, D.S. and Damle, N.K, 2006).
Fig. 1: Monobody
Nanobodies
Nanobodies are single domain antibodies that originate from camelids like Alpaca and Camel or cartilaginous fish like sharks (Stanfield et al., 2004; van der Linden et al., 1999) .
The nanobody family consist of conventional heterotetrameric antibodies with low-affinity binders (Harmsen MM, De Haard HJ, November 2007) as well as unique functional heavy (H)-chain antibodies (HCAbs) with high affinity binders (Harmsen MM, De Haard HJ, November 2007). Because a single polypeptide chain is expressed, they are better suited for phage display than Fragment antigen-binding (Fab) fragments (Holt L. J et al 2003). The H chain of these homodimeric antibodies consists of one antigen-binding domain, the VHH, and two constant domains. HCAbs fail to incorporate light (L) chains owing to the deletion of the first constant domain and a reshaped surface at the VHH side, which normally associates with L chains in conventional antibodies (Muyldermans, S, 2013).
Therefore, the production takes place in liquid cell culture and thus production in large quantities is simple with higher yields than Fab fragments (Holt L. J et al 2003). They consist of a single monomeric variable antibody domain and a universal Nanobody-framework (in our case cAbBCII10). With a size of 12-15 kDa they are slightly bigger than Monobodies but still able to penetrate hard tissues like solid tumours (Saerens, D.; Ghassabeh, G.; Muyldermans, S, 2008). Research lead to various applications in the therapeutically field. For example, a humanised scFv is in phase II testing to reduce mortality and myocardial infarction in patients undergoing graft surgery for coronary artery bypass (Holt L. J et al, 2003). Also therapeutically application against the influenza A H5N1 virus has been shown in mice where it reduced the replication rate significantly (Ibanez L. I. et al, 2011). Even in oral immunotherapy Nanobodies are used (Harmsen M. M. et al 2006). Also many diagnostically applications were made possible like super-resolution microscopy using a Nanobody tagged with GFP (Ries J. et al, 2012) or tagging by binding proteins, enzymes or antigens (Rothbauer U. et al, 2006) with such a complex (Rothbauer U. et al, 2007).They can also be modified to work as a biosensor (Saerens D. et al, 2005).
A high expression rate was shown in E. coli and they are still functional and stable even in absence of conserved disulphide bonds (Saerens et al., 2005) which are unlikely to form in the E. coli cytoplasm. Their high tolerance against acidic conditions, temperature (compared to mouse monoclonal antibodies (Van Der Linden R. et al, 1999), high solubility (Arbabi Ghahroudi M. et al, 1997) and very few cleavage sites for enzymes allow new areas of application (Harmsen, M. M.; Haard, H. J. de, 2007) . The Nanobody loop structure can bind to antigen structures inaccessible to human antibodies, for example catalytic centres in enzymes. Also fusion proteins and complexes can be created leaving both parts still active. Example are a complex of a shark Nanobody and lysozyme (Stanfield R. et al, 2004)(Desmyter A. et al, 1996) or a Nanobody conjugated branched Gold nanoparticle for photothermal therapy against tumour cells (Van De Broek B, 2011).
The nanobody family consist of conventional heterotetrameric antibodies with low-affinity binders (Harmsen MM, De Haard HJ, November 2007) as well as unique functional heavy (H)-chain antibodies (HCAbs) with high affinity binders (Harmsen MM, De Haard HJ, November 2007). Because a single polypeptide chain is expressed, they are better suited for phage display than Fragment antigen-binding (Fab) fragments (Holt L. J et al 2003). The H chain of these homodimeric antibodies consists of one antigen-binding domain, the VHH, and two constant domains. HCAbs fail to incorporate light (L) chains owing to the deletion of the first constant domain and a reshaped surface at the VHH side, which normally associates with L chains in conventional antibodies (Muyldermans, S, 2013).
Therefore, the production takes place in liquid cell culture and thus production in large quantities is simple with higher yields than Fab fragments (Holt L. J et al 2003). They consist of a single monomeric variable antibody domain and a universal Nanobody-framework (in our case cAbBCII10). With a size of 12-15 kDa they are slightly bigger than Monobodies but still able to penetrate hard tissues like solid tumours (Saerens, D.; Ghassabeh, G.; Muyldermans, S, 2008). Research lead to various applications in the therapeutically field. For example, a humanised scFv is in phase II testing to reduce mortality and myocardial infarction in patients undergoing graft surgery for coronary artery bypass (Holt L. J et al, 2003). Also therapeutically application against the influenza A H5N1 virus has been shown in mice where it reduced the replication rate significantly (Ibanez L. I. et al, 2011). Even in oral immunotherapy Nanobodies are used (Harmsen M. M. et al 2006). Also many diagnostically applications were made possible like super-resolution microscopy using a Nanobody tagged with GFP (Ries J. et al, 2012) or tagging by binding proteins, enzymes or antigens (Rothbauer U. et al, 2006) with such a complex (Rothbauer U. et al, 2007).They can also be modified to work as a biosensor (Saerens D. et al, 2005).
A high expression rate was shown in E. coli and they are still functional and stable even in absence of conserved disulphide bonds (Saerens et al., 2005) which are unlikely to form in the E. coli cytoplasm. Their high tolerance against acidic conditions, temperature (compared to mouse monoclonal antibodies (Van Der Linden R. et al, 1999), high solubility (Arbabi Ghahroudi M. et al, 1997) and very few cleavage sites for enzymes allow new areas of application (Harmsen, M. M.; Haard, H. J. de, 2007) . The Nanobody loop structure can bind to antigen structures inaccessible to human antibodies, for example catalytic centres in enzymes. Also fusion proteins and complexes can be created leaving both parts still active. Example are a complex of a shark Nanobody and lysozyme (Stanfield R. et al, 2004)(Desmyter A. et al, 1996) or a Nanobody conjugated branched Gold nanoparticle for photothermal therapy against tumour cells (Van De Broek B, 2011).
Fig. 2: Nanobody
References
- Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol 2012; 2012:980250; PMID:22474489; http://dx.doi.org/10.1155/2012/980250
- Arbabi Ghahroudi, M.; Desmyter, A.; Wyns, L.; Hamers, R.; Muyldermans, S. (1997). "Selection and identification of single domain antibody fragments from camel heavy-chain antibodies". FEBS Letters. 414 (3): 521–526. doi:10.1016/S0014-5793(97)01062-4. PMID 9323027.
- Bloom L, Calabro V (July 2009). "FN3: a new protein scaffold reaches the clinic". Drug Discov. Today. 14 (19–20): 949–55. doi:10.1016/j.drudis.2009.06.007. PMID 19576999.
- Batori, V. et al. (2002) Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. Protein Eng. 12, 1015–1020
- Desmyter, A.; Transue, T. R.; Ghahroudi, M. A.; Thi, M. H.; Poortmans, F.; Hamers, R.; Muyldermans, S.; Wyns, L. (1996). "Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme". Nature Structural Biology. 3 (9): 803–811. doi:10.1038/nsb0996-803. PMID 8784355.
- Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiterer S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G (2011). "Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis". Cell. 147: 306–19. doi:10.1016/j.cell.2011.08.046. PMC 3202669free to read. PMID 22000011.
- Gebauer, M. and Skerra, A. (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13, 1–1
- Gill, D.S. and Damle, N.K. (2006) Biopharmaceutical drug discovery using novel protein scaffolds. Curr. Opin. Biotechnol. 17, 653–658
- Harmsen, M. M.; Haard, H. J. de (2007): Properties, production, and applications of camelid single-domain antibody fragments. In Applied Microbiology and Biotechnology 77 (1), pp.13–22. DOI: 10.1007/s00253-007-1142-2.
- Harmsen, M. M.; Van Solt, C. B.; Van Zijderveld-Van Bemmel, A. M.; Niewold, T. A.; Van Zijderveld, F. G. (2006). "Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy". Applied Microbiology and Biotechnology. 72 (3): 544–551. doi:10.1007/s00253-005-0300-7. PMID 16450109.
- Harmsen MM, De Haard HJ (November 2007). "Properties, production, and applications of camelid single-domain antibody fragments". Appl. Microbiol. Biotechnol. 77 (1): 13–22. doi:10.1007/s00253-007-1142-2. PMC 2039825free to read. PMID 17704915.
- Holt, L. J.; Herring, C.; Jespers, L. S.; Woolven, B. P.; Tomlinson, I. M. (2003). "Domain antibodies: proteins for therapy". Trends in Biotechnology. 21 (11): 484–490. doi:10.1016/j.tibtech.2003.08.007. PMID 14573361.
- Ibanez, L. I.; De Filette, M.; Hultberg, A.; Verrips, T.; Temperton, N.; Weiss, R. A.; Vandevelde, W.; Schepens, B.; Vanlandschoot, P.; Saelens, X. (2011). "Nanobodies with in Vitro Neutralizing Activity Protect Mice Against H5N1 Influenza Virus Infection". Journal of Infectious Diseases. 203 (8): 1063–1072. doi:10.1093/infdis/jiq168. PMID 21450996.
- Koide, A; Koide, S (2007): Monobodies: antibody mimics based on the scaffoldof the fibronectin type III domain. In Methods in molecular biology (Clifton, N.J.) 352, pp.95–109. DOI: 10.1385/1-59745-187-8:95. [3] Lipovsek, D. (2010): Adnectins. Engineered target-binding protein therapeutics.
- Koide A, Bailey CW, Huang X, Koide S (December 1998). "The fibronectin type III domain as a scaffold for novel binding proteins". J. Mol. Biol. 284: 1141–51. doi:10.1006/jmbi.1998.2238. PMID 9837732.
- Koide S, Koide A, Lipovšek D (2012). "Target-binding proteins based on the 10th human fibronectin type III domain (¹⁰Fn3)". Meth. Enzymol. 503: 135–56. doi:10.1016/B978-0-12-396962-0.00006-9. PMID 22230568.
- Lipovsek, D. (2010): Adnectins. Engineered target-binding protein therapeutics. In Protein Engineering Design and Selection24 (1-2), pp.3–9. DOI: 10.1093/protein/gzq097.
- Muyldermans, S. (2013). "Nanobodies: Natural Single-Domain Antibodies". Annual Review of Biochemistry. 82: 775–797. doi:10.1146/annurev-biochem-063011-092449. PMID 23495938.
- Osoegawa K, de Jong PJ, Frengen E, Ioannou PA (May 2001). "Construction of bacterial artificial chromosome (BAC/PAC) libraries". Curr Protoc Hum Genet. Chapter 5: Unit 5.15. doi:10.1002/0471142905.hg0515s21. PMID 18428289.
- Rothbauer, U.; Zolghadr, K.; Tillib, S.; Nowak, D.; Schermelleh, L.; Gahl, A.; Backmann, N.; Conrath, K.; Muyldermans, S.; Cardoso, M. C.; Leonhardt, H. (2006). "Targeting and tracing antigens in live cells with fluorescent nanobodies". Nature Methods. 3 (11): 887–889. doi:10.1038/nmeth953. PMID 17060912.
- Rothbauer, U.; Zolghadr, K.; Muyldermans, S.; Schepers, A.; Cardoso, M. C.; Leonhardt, H. (2007). "A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins". Molecular & Cellular Proteomics. 7 (2): 282–289. doi:10.1074/mcp.M700342-MCP200. PMID 17951627.
- Ries, J.; Kaplan, C.; Platonova, E.; Eghlidi, H.; Ewers, H. (2012). "A simple, versatile method for GFP-based super-resolution microscopy via nanobodies". Nature Methods. 9 (6): 582–584. doi:10.1038/nmeth.1991. PMID 22543348. Saerens, D.; Pellis, M.; Loris, R.; Pardon, E.; Dumoulin, M.; Matagne, A. et al. (2005): Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. In Journal of molecular biology 352 (3), pp.597–607. DOI: 10.1016/j.jmb.2005.07.038.
- Saerens, D.; Ghassabeh, G.; Muyldermans, S. (2008). "Single-domain antibodies as building blocks for novel therapeutics". Current Opinion in Pharmacology. 8 (5): 600–608. doi:10.1016/j.coph.2008.07.006. PMID 18691671.
- Saerens, D.; Frederix, F.; Reekmans, G.; Conrath, K.; Jans, K.; Brys, L.; Huang, L.; Bosmans, E. N.; Maes, G.; Borghs, G.;
- Muyldermans, S. (2005). "Engineering Camel Single-Domain Antibodies and Immobilization Chemistry for Human Prostate-Specific Antigen Sensing". Analytical Chemistry. 77 (23): 7547–7555. doi:10.1021/ac051092j. PMID 16316161.
- Skerra, Arne (2007): Alternative non-antibody scaffolds for molecular recognition. In Protein technologies / Systems biology 18 (4), pp.295–304. DOI: 10.1016/j.copbio.2007.04.010..7
- Skerra, A. (2007) Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18, 295–304
- Stanfield, R.; Dooley, H.; Flajnik, M.; Wilson, I. (2004). "Crystal structure of a shark single-domain antibody V region in complex with lysozyme". Science. 305 (5691): 1770–1773. Bibcode:2004Sci...305.1770S. doi:10.1126/science.1101148. PMID 15319492.
- Stanfield, R.; Dooley, H.; Flajnik, M.; Wilson, I. (2004). "Crystal structure of a shark single-domain antibody V region in complex with lysozyme". Science. 305 (5691): 1770–1773. Bibcode:2004Sci...305.1770S. doi:10.1126/science.1101148. PMID 15319492
- Van Der Linden, R.; Frenken, L.; De Geus, B.; Harmsen, M.; Ruuls, R.; Stok, W.; De Ron, L.; Wilson, S.; Davis, P.; Verrips, C. T. (1999). "Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies". Biochimica et Biophysica Acta. 1431 (1): 37–46. doi:10.1016/S0167-4838(99)00030-8. PMID 10209277.
- Van Der Linden, R.; Frenken, L.; De Geus, B.; Harmsen, M.; Ruuls, R.; Stok, W.; De Ron, L.; Wilson, S.; Davis, P.; Verrips, C. T. (1999). "Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies". Biochimica et Biophysica Acta. 1431 (1): 37–46. doi:10.1016/S0167-4838(99)00030-8. PMID 10209277.
- Van De Broek, B.; Devoogdt, N.; d'Hollander, A.; Gijs, H. L.; Jans, K.; Lagae, L.; Muyldermans, S.; Maes, G.; Borghs, G. (2011). "Specific Cell Targeting with Nanobody Conjugated Branched Gold Nanoparticles for Photothermal Therapy". ACS Nano. 5 (6): 4319–4328. doi:10.1021/nn1023363. PMID 21609027.
